C4 Therapeutics, Inc. Gain (Loss) on Extinguishment of Debt
C4 Therapeutics, Inc. (CCCC) reported Gain (Loss) on Extinguishment of Debt of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2025-02-27
- C4 Therapeutics, Inc. gain (loss) on extinguishment of debt for the quarter ending 2024-12-31 was $0.00.
- C4 Therapeutics, Inc. gain (loss) on extinguishment of debt for the quarter ending 2024-09-30 was $0.00.
- C4 Therapeutics, Inc. gain (loss) on extinguishment of debt for the quarter ending 2023-12-31 was $0.00.
- C4 Therapeutics, Inc. gain (loss) on extinguishment of debt for the quarter ending 2023-09-30 was -$621.00K.
- C4 Therapeutics, Inc. gain (loss) on extinguishment of debt for fiscal 2024 was $0.00.
- C4 Therapeutics, Inc. gain (loss) on extinguishment of debt for fiscal 2023 was -$621.00K.
- C4 Therapeutics, Inc. gain (loss) on extinguishment of debt for fiscal 2022 was $0.00.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $0.00 derived: sum of 2 quarters · filed 2025-02-27 | $0.00 10-K · filed 2025-02-27 | |
| 2024-09-30 | $0.00 10-Q · filed 2024-10-31 | $0.00 10-Q · filed 2024-10-31 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$621.00K derived: sum of 2 quarters · filed 2025-02-27 | -$621.00K 10-K · filed 2025-02-27 | |
| 2023-09-30 | -$621.00K 10-Q · filed 2024-10-31 | -$621.00K 10-Q · filed 2024-10-31 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $0.00 derived: sum of 2 quarters · filed 2024-02-22 | $0.00 10-K · filed 2024-02-22 | |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-01 | $0.00 10-Q · filed 2023-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |